Key Takeaways & Executive Findings
- •• Global patent filings in cancer nanotechnology have surged, with China and the USA dominating innovation output. • Drug delivery systems and photothermal therapy are the most active research hotspots, reflecting clinical translation priorities. • The convergence of nanotechnology with immunotherapy and personalized medicine is a key emerging trend. • Bibliometric insights guide strategic R&D investment and policy formulation in cancer nanotechnology.
Abstract
Cancer nanotechnology has emerged as a transformative approach for targeted therapy, imaging, and diagnostics. This study presents a comprehensive bibliometric analysis of global patent landscapes and therapeutic innovations in cancer nanotechnology, covering publications and patents from 2000 to 2024. Using data from the Web of Science and Derwent Innovation Index, we identified key research trends, leading countries, institutions, and technology hotspots. The results reveal a rapid growth in patent filings, with China and the United States leading in innovation output. Major research themes include drug delivery systems, nanoparticles for photothermal therapy, and biosensors. The analysis highlights the increasing convergence of nanotechnology with immunotherapy and personalized medicine. Our findings provide strategic insights for researchers, policymakers, and industry stakeholders to navigate the evolving landscape of cancer nanotechnology.
1. Introduction
Cancer remains a leading cause of mortality worldwide, driving relentless efforts to develop more effective and targeted therapies. Nanotechnology has emerged as a promising frontier, offering unprecedented opportunities for early diagnosis, precise drug delivery, and minimally invasive treatments. The unique physicochemical properties of nanoparticles enable enhanced permeability and retention (EPR) effects, targeted cellular uptake, and controlled release of therapeutic agents, thereby improving treatment efficacy while reducing systemic toxicity.
Over the past two decades, the field of cancer nanotechnology has witnessed exponential growth, with a surge in research publications and patent filings. This growth reflects not only scientific curiosity but also substantial investment from both public and private sectors. However, the sheer volume of information makes it challenging to discern overarching trends, key players, and emerging technologies. Bibliometric analysis provides a systematic method to map the scientific and technological landscape, identify research hotspots, and forecast future directions.
This study aims to conduct a comprehensive bibliometric analysis of global patents and research articles in cancer nanotechnology. By analyzing publication and patent data, we seek to uncover the evolution of research themes, the geographical distribution of innovation, and the collaborative networks among institutions. Our findings will offer valuable insights for researchers, industry stakeholders, and policymakers to make informed decisions in this rapidly advancing field.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Chen, R. Liu, S. Gupta (2026). Global Trends in Cancer Nanotechnology: A Bibliometric Analysis of Patent Landscapes and Therapeutic Innovations. Chinese Journal of New Drugs. https://doi.org/10.1007/s40831-025-00987-2
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main research hotspots in cancer nanotechnology?
The main research hotspots include drug delivery systems, photothermal therapy, and biosensors, with a growing focus on combining nanotechnology with immunotherapy and personalized medicine.
Which countries lead in cancer nanotechnology patents?
China and the United States are the leading countries in terms of patent filings, reflecting their strong research infrastructure and investment in nanotechnology.
How has the field of cancer nanotechnology evolved over time?
The field has evolved from basic nanoparticle synthesis to sophisticated multifunctional platforms that integrate targeting, imaging, and therapy, with a recent trend towards combination with immunotherapeutic approaches.
What is the significance of bibliometric analysis in this context?
Bibliometric analysis helps identify research trends, key players, and emerging technologies, providing strategic insights for R&D planning and policy-making.
What are the future directions in cancer nanotechnology?
Future directions include the development of personalized nanomedicine, combination therapies, and the translation of nanocarriers from bench to bedside, addressing challenges such as scalability and regulatory approval.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.